Adoptive transfer of HER2/neu-specific T cells expanded with alternating gamma chain cytokines mediate tumor regression when combined with the depletion of myeloid-derived suppressor cells

Johanna K. Morales, MacIej Kmieciak, Laura Graham, Marta Feldmesser, Harry D. Bear, Masoud H. Manjili

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Adoptive immunotherapy (AIT) using ex vivo-expanded HER-2/neu-specific T cells has shown initial promising results against disseminated tumor cells in the bone marrow. However, it has failed to promote objective responses against primary tumors. We report for the first time that alternating gamma chain cytokines (IL-2, IL-7 and IL-15) ex vivo can expand the neu-specific lymphocytes that can kill breast tumors in vitro. However, the anti-tumor efficacy of these neu-specific T cells was compromised by the increased levels of myeloid-derived suppressor cells (MDSC) during the premalignant stage in FVBN202 transgenic mouse model of breast carcinoma. Combination of AIT with the depletion of MDSC, in vivo, resulted in the regression of neu positive primary tumors. Importantly, neu-specific antibody responses were restored only when AIT was combined with the depletion of MDSC. In vitro studies determined that MDSC caused inhibition of T cell proliferation in a contact-dependent manner. Together, these results suggest that combination of AIT with depletion or inhibition of MDSC could lead to the regression of mammary tumors.

Original languageEnglish (US)
Pages (from-to)941-953
Number of pages13
JournalCancer Immunology, Immunotherapy
Volume58
Issue number6
DOIs
StatePublished - Jun 2009

Fingerprint

Adoptive Transfer
Adoptive Immunotherapy
Cytokines
T-Lymphocytes
Neoplasms
Breast Neoplasms
Interleukin-15
Interleukin-7
Bone Marrow Cells
Transgenic Mice
Antibody Formation
Interleukin-2
Cell Proliferation
Myeloid-Derived Suppressor Cells
Lymphocytes

Keywords

  • Adoptive immunotherapy
  • Breast cancer
  • Gamma chain cytokines
  • HER-2/neu
  • Myeloid-derived suppressor cells

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Immunology
  • Immunology and Allergy

Cite this

Adoptive transfer of HER2/neu-specific T cells expanded with alternating gamma chain cytokines mediate tumor regression when combined with the depletion of myeloid-derived suppressor cells. / Morales, Johanna K.; Kmieciak, MacIej; Graham, Laura; Feldmesser, Marta; Bear, Harry D.; Manjili, Masoud H.

In: Cancer Immunology, Immunotherapy, Vol. 58, No. 6, 06.2009, p. 941-953.

Research output: Contribution to journalArticle

Morales, Johanna K. ; Kmieciak, MacIej ; Graham, Laura ; Feldmesser, Marta ; Bear, Harry D. ; Manjili, Masoud H. / Adoptive transfer of HER2/neu-specific T cells expanded with alternating gamma chain cytokines mediate tumor regression when combined with the depletion of myeloid-derived suppressor cells. In: Cancer Immunology, Immunotherapy. 2009 ; Vol. 58, No. 6. pp. 941-953.
@article{ed1ad8b0ad764ab59b59f26ed86b0422,
title = "Adoptive transfer of HER2/neu-specific T cells expanded with alternating gamma chain cytokines mediate tumor regression when combined with the depletion of myeloid-derived suppressor cells",
abstract = "Adoptive immunotherapy (AIT) using ex vivo-expanded HER-2/neu-specific T cells has shown initial promising results against disseminated tumor cells in the bone marrow. However, it has failed to promote objective responses against primary tumors. We report for the first time that alternating gamma chain cytokines (IL-2, IL-7 and IL-15) ex vivo can expand the neu-specific lymphocytes that can kill breast tumors in vitro. However, the anti-tumor efficacy of these neu-specific T cells was compromised by the increased levels of myeloid-derived suppressor cells (MDSC) during the premalignant stage in FVBN202 transgenic mouse model of breast carcinoma. Combination of AIT with the depletion of MDSC, in vivo, resulted in the regression of neu positive primary tumors. Importantly, neu-specific antibody responses were restored only when AIT was combined with the depletion of MDSC. In vitro studies determined that MDSC caused inhibition of T cell proliferation in a contact-dependent manner. Together, these results suggest that combination of AIT with depletion or inhibition of MDSC could lead to the regression of mammary tumors.",
keywords = "Adoptive immunotherapy, Breast cancer, Gamma chain cytokines, HER-2/neu, Myeloid-derived suppressor cells",
author = "Morales, {Johanna K.} and MacIej Kmieciak and Laura Graham and Marta Feldmesser and Bear, {Harry D.} and Manjili, {Masoud H.}",
year = "2009",
month = "6",
doi = "10.1007/s00262-008-0609-z",
language = "English (US)",
volume = "58",
pages = "941--953",
journal = "Medical Oncology and Tumor Pharmacotherapy",
issn = "0340-7004",
publisher = "Springer Science and Business Media Deutschland GmbH",
number = "6",

}

TY - JOUR

T1 - Adoptive transfer of HER2/neu-specific T cells expanded with alternating gamma chain cytokines mediate tumor regression when combined with the depletion of myeloid-derived suppressor cells

AU - Morales, Johanna K.

AU - Kmieciak, MacIej

AU - Graham, Laura

AU - Feldmesser, Marta

AU - Bear, Harry D.

AU - Manjili, Masoud H.

PY - 2009/6

Y1 - 2009/6

N2 - Adoptive immunotherapy (AIT) using ex vivo-expanded HER-2/neu-specific T cells has shown initial promising results against disseminated tumor cells in the bone marrow. However, it has failed to promote objective responses against primary tumors. We report for the first time that alternating gamma chain cytokines (IL-2, IL-7 and IL-15) ex vivo can expand the neu-specific lymphocytes that can kill breast tumors in vitro. However, the anti-tumor efficacy of these neu-specific T cells was compromised by the increased levels of myeloid-derived suppressor cells (MDSC) during the premalignant stage in FVBN202 transgenic mouse model of breast carcinoma. Combination of AIT with the depletion of MDSC, in vivo, resulted in the regression of neu positive primary tumors. Importantly, neu-specific antibody responses were restored only when AIT was combined with the depletion of MDSC. In vitro studies determined that MDSC caused inhibition of T cell proliferation in a contact-dependent manner. Together, these results suggest that combination of AIT with depletion or inhibition of MDSC could lead to the regression of mammary tumors.

AB - Adoptive immunotherapy (AIT) using ex vivo-expanded HER-2/neu-specific T cells has shown initial promising results against disseminated tumor cells in the bone marrow. However, it has failed to promote objective responses against primary tumors. We report for the first time that alternating gamma chain cytokines (IL-2, IL-7 and IL-15) ex vivo can expand the neu-specific lymphocytes that can kill breast tumors in vitro. However, the anti-tumor efficacy of these neu-specific T cells was compromised by the increased levels of myeloid-derived suppressor cells (MDSC) during the premalignant stage in FVBN202 transgenic mouse model of breast carcinoma. Combination of AIT with the depletion of MDSC, in vivo, resulted in the regression of neu positive primary tumors. Importantly, neu-specific antibody responses were restored only when AIT was combined with the depletion of MDSC. In vitro studies determined that MDSC caused inhibition of T cell proliferation in a contact-dependent manner. Together, these results suggest that combination of AIT with depletion or inhibition of MDSC could lead to the regression of mammary tumors.

KW - Adoptive immunotherapy

KW - Breast cancer

KW - Gamma chain cytokines

KW - HER-2/neu

KW - Myeloid-derived suppressor cells

UR - http://www.scopus.com/inward/record.url?scp=63949088142&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=63949088142&partnerID=8YFLogxK

U2 - 10.1007/s00262-008-0609-z

DO - 10.1007/s00262-008-0609-z

M3 - Article

C2 - 18979098

AN - SCOPUS:63949088142

VL - 58

SP - 941

EP - 953

JO - Medical Oncology and Tumor Pharmacotherapy

JF - Medical Oncology and Tumor Pharmacotherapy

SN - 0340-7004

IS - 6

ER -